ST Pharm Co.,Ltd. (KOSDAQ:237690)

South Korea flag South Korea · Delayed Price · Currency is KRW
168,700
+1,200 (0.72%)
Apr 28, 2026, 3:30 PM KST
118.81%
Market Cap 3.49T
Revenue (ttm) 331.68B
Net Income (ttm) 54.99B
Shares Out 20.84M
EPS (ttm) 2,688.35
PE Ratio 62.31
Forward PE 53.94
Dividend 500.00 (0.34%)
Ex-Dividend Date Mar 30, 2026
Volume 292,916
Average Volume 143,548
Open 167,500
Previous Close 167,500
Day's Range 161,900 - 172,100
52-Week Range 70,800 - 172,000
Beta 0.35
RSI 66.56
Earnings Date Apr 27, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1983
Employees 655
Stock Exchange KOSDAQ
Ticker Symbol 237690
Full Company Profile

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.

Financial Statements

News

There is no news available yet.